DrugDashboards

Piperacillin and Tazobactam

Piperacillin Sodium,tazobactam Sodium · PIPERACILLIN SODIUM 3 g/15mL; TAZOBACTAM SODIUM .375 g/15mL · Injection, Powder, For Solution · Intravenous · Fresenius Kabi USA, LLC

NDC 63323-0300-30 · 10 VIAL in 1 BOX / 15 mL in 1 VIAL · ANDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. Historically, drugs in this position went on to a new shortage within 90 days about 0.5% of the time — roughly 4× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.5%chance of a new FDA shortage posting for piperacillin sodium and tazobactam sodium (injectable) in the next 90 days

sterile injectable · OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 4× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA065523
TE code
AP
Approval date
May 31, 2011
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Piperacillin Sodium,tazobactam Sodium (Injection, Powder, For Solution)

LabelerStrengthFirst seenLast seen
Fresenius Kabi USA, LLCPIPERACILLIN SODIUM 3 g/15mL; TAZOBACTAM SODIUM .375 g/15mLJul 15, 2026Sep 3, 2026
WG Critical Care, LLCPIPERACILLIN SODIUM 2 g/1; TAZOBACTAM SODIUM .25 g/1Jul 15, 2026Sep 2, 2026
WG Critical Care, LLCPIPERACILLIN SODIUM 3 g/1; TAZOBACTAM SODIUM .375 g/1Jul 15, 2026Sep 2, 2026
WG Critical Care, LLCPIPERACILLIN SODIUM 4 g/1; TAZOBACTAM SODIUM .5 g/1Jul 15, 2026Sep 2, 2026
Fresenius Kabi USA, LLCPIPERACILLIN SODIUM 2 g/10mL; TAZOBACTAM SODIUM .25 g/10mLJul 15, 2026Aug 31, 2026
Fresenius Kabi USA, LLCPIPERACILLIN SODIUM 4 g/20mL; TAZOBACTAM SODIUM .5 g/20mLJul 15, 2026Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Piperacillin and Tazobactam — NDC 63323-0300-30," retrieved September 3, 2026, https://drugdashboards.com/drug/63323030030.

Free to cite with attribution — see how the data is put together.